RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis.

Background: The randomized, phase 2 RENEW trial (NCT01721161) evaluated efficacy/safety of opicinumab (anti-LINGO-1) versus placebo in patients with first-episode unilateral acute optic neuritis (AON). Although no significant differences in the latency recovery of visual evoked potential (VEP) were observed between opicinumab and placebo groups in the intention to treat (ITT) population, the prespecified per-protocol (PP) population showed better recovery with opicinumab than with placebo. RENEWED (NCT02657915) was a one-visit, follow-up study 2 years after the last RENEW study visit (Week 32) designed to assess the long-term electrophysiological and clinical outcomes for participants previously enrolled and having received study treatment in RENEW.

Twenty-four Month Multidisciplinary Follow-up of Multisystemic Inflammatory Syndrome Patients in a Tertiary Pediatric Hospital in Chile: A Prospective Study.

Multisystemic inflammatory syndrome (MIS-C) is a severe postinfectious condition. This study aims to detail long-term follow-up. Forty-five patients were followed up for 24 months, inflammatory markers were normalized at 3 months and echocardiographic alterations were resolved in all patients at 6 months, remaining normal.

Xylazine-Induced Necrotic Skin Ulcers in a Fentanyl-Injecting Individual in South Florida, United States: A Case Report.

Xylazine, commonly referred to as "Tranq," is an alpha-2-adrenergic receptor agonist that is FDA-approved only as a sedative and tranquilizer for veterinary use. However, its use as an adulterant in various illicit drugs, including fentanyl, has been on the rise, leading to its street name, "Tranq-Dope." Intravenous injection use of xylazine produces distinctive skin ulceration with accompanying necrosis, which can be considered virtually pathognomonic.

Enhancing photodynamic and radionuclide therapy by small interfering RNA (siRNA)-RAD51 transfection via self-emulsifying delivery systems (SNEDDS).

Background Aims: Gene-silencing by small interfering RNA (siRNA) is an attractive therapy to regulate cancer death, tumor recurrence or metastasis. Because siRNAs are easily degraded, it is necessary to develop transport and delivery systems to achieve efficient tumor targeting. Self-nanoemulsifying systems (SNEDDS) have been successfully used for pDNA transport and delivery, so they may be useful for siRNA.